Compositions and methods for increasing protein half-life in a serum

Abstract

Novel antibodies, such as single domain antibodies (sdAbs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a Section 371 of International Application No. PCT / US2014 / 045768, filed Jul. 8, 2014, which was published Jan. 15, 2015 under International Publication No. WO 2015 / 006337 A2, which claims priority to U.S. Provisional Patent Application No. 61 / 843,628 filed Jul. 8, 2013, the disclosures of which are incorporated herein by reference.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY[0002]This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name “00830858.txt,” creation date of Jul. 7, 2014, and having a size of 41 kb. The sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.BACKGROUND OF THE INVENTION[0003]Pharmacokinetics of a drug candidate is a critical parameter and often largely determines whether or not the drug candidate will be further developed into a...

AI Technical Summary

Benefits of technology

[0020](2) exposing the fusion protein to the transferrin to thereby increase the half-life of the target protein in the fusion protein compared to the target protein alone.

[0027]The present invention also relates to a method comprising exposing a composition according to an embodiment of the present invention to the transferrin to thereby increase the half-life of the target protein in the fusion protein.

Problems solved by technology

In particular, pharmacokinetic studies of protein- and peptide-based therapeutics, including antibodies, have demonstrated that such therapeutics have varying serum half lives, and those peptides and proteins with a short serum half-life, although having a promising therapeutic potential, are thus often unsuitable for further drug development.

Unfortunately, these technologies suffer from complications including complex manufacturing and characterization processes, low expression levels, and undesired functions of the generated molecules.

However, the use of antibodies and antibody fragments such as sdAbs against transferrin, for increasing the serum half-life of peptidic molecules has not been reported.

Images